Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

10
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
10
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials01:16

Clinical Trials

6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Effects of EDTA on End-Point Detection Methods01:18

Effects of EDTA on End-Point Detection Methods

306
Different methods, such as visual observance of metal-ion indicators, spectroscopic techniques, and potentiometric methods, can determine the endpoint of an EDTA titration.
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
306

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Diagnostic Yield of Cardiac CT to Detect Cardiac Thrombi in Patients With Acute Ischemic Stroke (AIS of HEARTS).

Stroke·2026
Same author

Case Fatality of Subarachnoid Hemorrhage by Aneurysm Location: A Population-Based Study From Finland and New Zealand.

Neurology·2026
Same author

Stroke and climate change: A World Stroke Organization scientific statement.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

High-income country-supported telestroke thrombolysis to a lower-middle income country: an international proof-of-concept case report.

BMJ neurology open·2026
Same author

Aotearoa New Zealand's neurologist workforce: a 2024 analysis of demand, supply and projections.

BMJ neurology open·2026
Same author

Ultra-early computed tomography markers of haematoma expansion: Potential trial targets?

European stroke journal·2026
Same journal

Clinical characteristics and outcomes of intracerebral haemorrhage in young vs older adults: insights from the INTERACT3 trial.

European stroke journal·2026
Same journal

Correction to: Stroke Action Plan for Europe 2018-2030 (SAP-E): mid-term review and update.

European stroke journal·2026
Same journal

Regional inequities in acute stroke care in Norway: a national benchmark for the "stroke action plan for Europe" implementation.

European stroke journal·2026
Same journal

Incidence and outcome of paediatric cardioembolic stroke: a nationwide population-based study.

European stroke journal·2026
Same journal

Procedure time and 90-day outcomes after endovascular thrombectomy for large-core stroke.

European stroke journal·2026
Same journal

Long-term risk of major adverse cardiovascular events after carotid endarterectomy-a 9-year prospective cohort study of the Athero-Express biobank.

European stroke journal·2026
查看所有相关文章

相关实验视频

Updated: Jul 21, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

21.9K

Tenecteplase真实世界数据:一个三相序列比较.

Anna Ranta1,2, Alicia Tyson1, Bhavesh Lallu3

  • 1Wellington Regional Hospital, Wellington, New Zealand.

European stroke journal
|July 25, 2023
PubMed
概括
此摘要是机器生成的。

在中风血栓溶解中使用tenecteplase与alteplase相比,显示出更好的结果和更快的治疗时间. 这些好处并不是由于时间混,支持tenecteplase.

关键词:
一次性中风,中风.转流是指转流的意思,是指转流的意思.没有替代品.血栓溶解是一种血栓溶解.

更多相关视频

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.8K

相关实验视频

Last Updated: Jul 21, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

21.9K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

2.8K

科学领域:

  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.
  • 公共卫生 公共卫生

背景情况:

  • 新西兰中部地区中风网络在2020年从阿尔特普拉斯转换为特内克特普拉斯用于中风血栓溶解,然后在2021年由于药物供应问题而恢复使用阿尔特普拉斯.
  • 这种意外的转换为评估治疗疗效和潜在的时间混提供了独特的机会.

研究的目的:

  • 在中风血栓溶解中,评估与高高相比,基的现实有效性.
  • 为了确定是否观察到的tenecteplase的益处受到时间趋势的影响,而不是药物本身.

主要方法:

  • 在新西兰中部地区中风网络中,对从2018年1月到2022年12月的中风患者数据进行了回顾性分析.
  • 患者结局的比较,包括有利的修改兰金尺度 (mRS) 评分,门到针 (DTN) 时间,针到部 (NTG) 时间和症状性脑内出血 (sICH) 率.
  • 对回归分析进行了调整,以考虑关键的临床因素和血栓切除术的使用.

主要成果:

  • 1121名患者接受了阿尔特,286名患者接受了.
  • 乙烯基与更高的有利功能结果几率 (aOR=1.43) 和显著更短的DTN和NTG时间有关.
  • 带有症状的脑内出血的发生率较低,与丁氏甲 (aOR=0.29),这些发现在比较丁氏甲与晚期高氏甲期间时仍然存在.

结论:

  • 在真实世界中风治疗环境中观察到的tenecteplase的益处不太可能是由于时间混.
  • 与阿尔特普拉斯相比,坦克特普拉斯在中风血栓溶解中表现出更高的疗效和安全性.
  • 这些发现支持在中风管理方案中继续使用和考虑 Tenecteplase.